
labcorp lead refer laboratori test
compani also oper covanc drug develop
chiltern
laboratori corpor america hold
diagnost tool
labcorp deliv mix bolt envigo
reiter hold rais pt
labcorp deliv earn beat came street revenu
fell short covanc rel street estim expect labcorp
top line pressur growth came driven impact relat pama
loss exclus unitedhealthcar horizon lighter covanc revenu help
combat pressur lh announc acquir envigo expect add
revenu annual run-rat basi reiter hold rate rais
pt use multipl adj ep
result mix rev y/i miss
street reduct revenu driven
divestitur fx partial off-set
organ revenu adj ep beat part help
share buyback
labcorp diagnost dx rev driven
impact due pama partial off-set organ dx volum growth
manag care contract chang result impact organ volum coupl
one less day quarter partial off-set favor weather
benefit revenue /req
covanc covanc rev y/i fxn miss
said exclud pass-through covanc organ revenu exceed fx result
impact rev partial off-set organ
revenu growth om covanc came y/i
lh select prefer lab unit lh lost exclus
select one prefer lab along quest ameripath/dermpath
subsidiari biorefer lab genedx invita mayo
clinic lab join prefer lab network pln launch juli
bolt envigo mid-april lh announc acquisit envigo nonclin
research servic busi cash envigo rev
add envigo revenu model
envigo busi includ facil eu us increas covanc
nonclin research employe base employe global
reiter revenue guid tick ep guid lh reiter revenue growth guid
rais adj ep guid flat
guid assum declin lh diagnost growth
covanc includ half year envigo lh maintain guid
plan activ deploy share buyback
expect flat y/i growth lh note saw slight benefit dtc
expect flat slightli y/i growth dtc genet test
lh declin elabor suspect may upgrad
technolog enabl greater health insight patient reduc test
discount lower tv ad spend
model discuss model chang page
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
laboratori corpor america hold
covanc deliv line lh expect covanc revenu declin
larg due headwind fx growth fxn coupl neg
impact relat passthrough exclud impact pass-through lh indic
covanc busi grew consist fy guidanc rang
lh deliv book-to-bil slight downtick prior quarter
exit backlog expect convert revenu
next month lh look covanc drive total compani revenu growth
guid revenu growth core diagnost segment
share-shift start play competitor quest deliv strong
volum growth street estim lh report volum growth
includ neg impact manag care chang
came last week indic expect volum growth build
year primarili new live target opportun time
said lh indic saw volum loss relat quest januari
saw trend stabil februari march
 buyback key compon lh capit deploy repurchas
stock lh author buy-back plan bought back
lh indic light year activ
expect featur increas tuck-in deal lh discuss sever
health system believ industri awar impact pama risen
consum initi move forward lh indic call plan
open least site end labcorp walgreen partnership
indic track open least locat
model updat look total compani revenu growth y/i
prior assum diagnost covanc growth
previous rais revenue adj ep
y/i new estim includ
hold unchang target price may
diagnost tool
laboratori corpor america hold
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold unchang target price may
diagnost tool
laboratori corpor america hold
hold unchang target price may
diagnost tool
laboratori corpor america hold
